Non-Muscle Invasive Bladder Cancer VL

Implementing Nadofaragene Firadenovec Treatment in NMIBC - Mark Tyson, Aimee Boden, & Meghann Davis

Details
Zachary Klaassen hosts Mark Tyson, Aimee Boden, and Meghann Davis, to discuss the implementation of Adstiladrin treatment in the clinic setting. They discuss the logistics of offering this FDA approved based on the phase III trial demonstrating significant efficacy in BCG-unresponsive non-muscle invasive bladder cancer. The team at Mayo Clinic began administering Adstiladrin in late November 2023....

Sequential Gemcitabine and Docetaxel Shows Promise for Intermediate-Risk NMIBC - Vignesh Packiam

Details
Sam Chang hosts a conversation with Vignesh Packiam to discuss the emerging role of intravesical gemcitabine and docetaxel (gem/doce) for treating non-muscle invasive bladder cancer (NMIBC), spotlighting Dr. Packiam's recent publication in Urologic Oncology. The study, a retrospective review focusing on AUA intermediate-risk NMIBC patients, demonstrates the regimen's efficacy and tolerability. It...

Intravesical Gemcitabine-Docetaxel Shows Durable Response in Recurrent High-Risk NMIBC After BCG - Mark Preston

Details
Sam Chang hosts a conversation with Mark Preston discussing innovative chemotherapy combinations for non-muscle invasive bladder cancer. Drawing inspiration from Dr. Mike O'Donnell's work with gemcitabine and docetaxel, Dr. Preston's team sought to replicate these promising results. Their multi-institutional retrospective analysis examined over 100 patients treated with this regimen after BCG ther...

Age Alone Should Not Preclude BCG Therapy in NMIBC - Ashish Kamat

Details
Sam Chang converses with Ashish Kamat about a study exploring age's influence on treatment outcomes for non-muscle invasive bladder cancer patients. Despite common beliefs that older patients may not respond as well to intravesical therapy, their research challenges this notion, suggesting age should not deter from appropriate treatment. Utilizing a robust dataset, they found no significant differ...

Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC: A Discussion on the BOND-003 and CORE1 Trials - Trinity Bivalacqua

Details
Sam Chang converses with Trinity Bivalacqua about treatments in non-muscle invasive bladder cancer, focusing on Cretostimogene grenadenorepvec (Creto), an oncolytic adenovirus, CG0070. Dr. Bivalacqua discusses trials exploring Creto's efficacy in managing BCG-unresponsive CIS, emphasizing its dual mechanism of action: direct tumor lysis and immune system activation. Initial results from the BOND-0...

Understanding BCG Unresponsive NMIBC: Patient Perspectives, Treatment Options, and Clinical Guidance - Gautam Jayram

Details
Ashish Kamat is joined by Gautam Jayram to unravel the complexities of BCG unresponsiveness in bladder cancer treatment. Dr. Jayram emphasizes the importance of understanding what constitutes adequate BCG treatment, highlighting the necessity of more than just six initial doses for accurate classification of BCG unresponsiveness. He sheds light on the challenges and disparities in BCG access, part...

Understanding Risk Stratification in Non-Muscle Invasive Bladder Cancer: Applying AUA Guidelines in Clinical Practice - Neal Shore

Details
Ashish Kamat is joined by Neal Shore to delve into risk stratification in non-muscle invasive bladder cancer (NMIBC). Dr. Shore highlights the crucial role of the AUA guidelines, developed with significant contributions from Dr. Kamat and others, in differentiating patients into low, intermediate, and high-risk categories. This stratification informs the frequency of cystoscopies, the intensity of...

Impact of Agent Orange Exposure on Non-Muscle Invasive Bladder Cancer Outcomes - Kyle Richards

Details
Kyle Richards delves into the subject of environmental factors influencing bladder cancer, particularly focusing on the potential carcinogenic effects of Agent Orange on non-muscle invasive bladder cancer. Dr. Richards highlights the recognition of Agent Orange by the VA as a linked carcinogen to bladder cancer, allowing veterans exposure benefits. Through an observational retrospective study invo...

Combining Pembrolizumab and BCG Immunotherapies: The KEYNOTE-676 Trial in High-Risk NMIBC - Neal Shore

Details
Sam Chang converses with Neal Shore about the KEYNOTE-676 trial, focusing on combining pembrolizumab with BCG for high-risk NMIBC patients previously treated with BCG. This study aims to explore the potential synergy between two immunotherapeutic agents, leveraging pembrolizumab's success in MIBC to improve outcomes in NMIBC. With enrollment progressing well, the trial signals a collaborative futu...

The Role of Gene Therapy in Enhancing Bladder Cancer Patient Outcomes - Mark Tyson

Details
Neal Shore and Mark Tyson discuss advances in non-muscle invasive bladder cancer treatments, particularly for BCG unresponsive patients. They delve into the approval and data on nadofaragene firadenovec, a novel intravesical gene therapy, highlighting its efficacy and patient-friendly administration schedule. Dr. Tyson shares insights on the drug's mechanism, its clinical trial outcomes, and its o...